Because the genetic and/or environmental causes of ALS for the majority of the patients are not known, our findings of a benefit by P110 treatment in three forms of familial ALS are encouraging. Also encouraging are our findings of treatment benefits in symptomatic mice, as most patients are diagnosed at the symptomatic stage of the disease. The progression of disease in the SOD1G93A mouse model is rather rapid, resulting in many groups performing therapeutic pilot studies in the SOD1G93A mouse model beginning at the presymptomatic stage between 30 and 60 days of age, long before clinical symptoms are observed (Turner & Talbot, 2008; Eisen et al, 2014). Since in most cases, ALS is a sporadic disease, treatment at presymptomatic stage is clinically less relevant. Furthermore, P110 treatment significantly improved survival after the onset of the symptoms to 37 ± 5 days compared to vehicle 28 ± 5 days, which compare favorably with the data previously published using edaravone (Ito et al, 2008).